Singapur - inglise - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 50u/ml - hepatitis a virus (inactivated) 50u/ml

Singapur - inglise - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 25 u/0.5 ml - hepatitis a virus (inactivated) 25 u/0.5 ml

Euroopa Liit - inglise - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

Kanada - inglise - Health Canada

glaxosmithkline inc - hepatitis a virus, inactivated; hepatitis b surface antigen (recombinant) - suspension - 720unit; 20mcg - hepatitis a virus, inactivated 720unit; hepatitis b surface antigen (recombinant) 20mcg - vaccines

Kanada - inglise - Health Canada

glaxosmithkline inc - hepatitis b surface antigen (recombinant); hepatitis a virus, inactivated - suspension - 10mcg; 360unit - hepatitis b surface antigen (recombinant) 10mcg; hepatitis a virus, inactivated 360unit - vaccines

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

Kanada - inglise - Health Canada

valneva austria gmbh - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) - suspension - 6mcg - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) 6mcg - vaccines

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 15 lf u; pertactin 3ug; pertussis filamentous haemagglutinin 20ug; pertussis fimbriae 2+3 5ug; pertussis toxoid, adsorbed 20ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (m e f 1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 5 lf u - suspension for injection - active: diphtheria toxoid, adsorbed 15 lf u pertactin 3ug pertussis filamentous haemagglutinin 20ug pertussis fimbriae 2+3 5ug pertussis toxoid, adsorbed 20ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (m e f 1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 5 lf u excipient: aluminium phosphate formaldehyde glutaral neomycin phenoxyethanol polymyxin b polysorbate 80 water for injection - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis and poliomyelitis. quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.

Iisrael - inglise - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

Iisrael - inglise - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.